← Leaderboards
Hua Liu
University Of Texas Med Br Galveston
$4,776,133
Attributed
$6,948,926
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2020–25$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,948,926 · 4
By mechanism
R01$6,948,926 · 4
Top collaborators
- Xiaodong Cheng5 shared
- Maria-Adelaide Micci1 shared
- Massoud Motamedi1 shared
- Bartosz Rafal Szczesny1 shared
Most similar at University Of Texas Med Br Galveston
Same institution · by research overlap
- Wenbo Zhang$11,264,299
- Maria-Adelaide Micci$4,048,365
- Bartosz Rafal Szczesny$632,279
Others in their field
Other Emerging Leaders on “Play”
- Chanza Baytop · Westat, Inc.$271,217,917
- John E West · University Of Texas At Austin$97,000,000
- Scott Topper · Broad Institute, Inc.$40,042,399
- Priyamvada Acharya · Duke University$22,519,941
- Bronwen Shaw · Medical College Of Wisconsin$19,560,999
- Oliver Brand · Emory University$18,288,469
Research focus
PlayRetinaBlindnessMediatingNovel TherapeuticsMolecularPreventMouse ModelFunctional DisorderGeneticRetinal IschemiaKnockout MiceProteinsPreventionReperfusion TherapyFaceEndotheliumBiologyRetinal DiseasesChronicRetinal Ganglion CellsEndothelial CellsNerve DegenerationAging
Grant awards (15)
The Role of Sirt6 in Acrolein-Induced Ocular Injury$1,447,549
R01 · FY2025 · EY · contact PI
The Role of mtDNA/ZBP1 in Retinal Neurodegeneration$618,088
R01 · FY2025 · EY · contact PI
Epac1 as a novel therapeutic target for diabetic retinopathy$506,223
R01 · FY2025 · EY
Epac1 as a novel therapeutic target for diabetic retinopathy$40,487
R01 · FY2025 · EY
Epac1 as a novel therapeutic target for diabetic retinopathy$506,223
R01 · FY2024 · EY
Neuroprotective Role of Sirt6 in Glaucoma$441,997
R01 · FY2024 · EY · contact PI
Epac1 as a novel therapeutic target for diabetic retinopathy$506,223
R01 · FY2023 · EY
Neuroprotective Role of Sirt6 in Glaucoma$441,997
R01 · FY2023 · EY · contact PI
Epac1 as a novel therapeutic target for diabetic retinopathy$514,763
R01 · FY2022 · EY
Neuroprotective Role of Sirt6 in Glaucoma$428,738
R01 · FY2022 · EY · contact PI
Neuroprotective Role of Sirt6 in Glaucoma$75,084
R01 · FY2022 · EY · contact PI
Neuroprotective Role of Sirt6 in Glaucoma$501,546
R01 · FY2021 · EY · contact PI
AD-focused Administrative Supplement for NIH Grant Neuroprotective Role of Sirt6 in Glaucoma$395,000
R01 · FY2021 · EY · contact PI
Neuroprotective Role of Sirt6 in Glaucoma$449,924
R01 · FY2020 · EY · contact PI
Neuroprotective Role of Sirt6 in Glaucoma$75,084
R01 · FY2020 · EY · contact PI